Liverpool HIV Interactions

Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Potential Weak Interaction

Rilpivirine (RPV)

Dolutegravir/Abacavir/ Lamivudine (DTG/ABC/3TC)

Quality of Evidence: Very Low

Summary:

Triumeq (dolutegravir, abacavir, lamivudine) is indicted for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with rilpivirine would be possible from a pharmacokinetic standpoint. No clinically significant pharmacokinetic interaction was observed between rilpivirine and dolutegravir. Coadministration of rilpivirine (25 mg once daily) and dolutegravir (50 mg once daily) increased dolutegravir Cmax, AUC and Ctrough by 13%, 12% and 22%, respectively. Rilpivirine Cmax, AUC and Ctrough increased by 10%, 6% and 21%, respectively. No interaction is expected with abacavir or lamivudine.

Description:

Coadministration of rilpivirine and dolutegravir increased dolutegravir AUC, Cmax and Ctrough by 12%, 13% and 22%, respectively. There was no effect on rilpivirine. No dose adjustment is necessary.

Triumeq Summary of Product Characteristics, ViiV Healthcare, June 2019.

In drug interaction trials, dolutegravir did not have a clinically relevant effect on the pharmacokinetics of rilpivirine. Rilpivirine had no clinically significant effect on the pharmacokinetics of dolutegravir. Coadministration of rilpivirine (25 mg once daily) and dolutegravir (50 mg once daily) to 16 subjects increased dolutegravir Cmax, AUC and Ctrough by 13%, 12% and 22%, respectively. Rilpivirine Cmax, AUC and Ctrough increased by 10%, 6% and 21%, respectively.

Triumeq US Prescribing Information, ViiV Healthcare, May 2019.

Coadministration of dolutegravir (50 mg once daily) and rilpivirine (25 mg once daily) was studied in 16 HIV-negative subjects. Rilpivirine increased dolutegravir AUC, Cmax and Ctrough by 12%, 13% and 22%, respectively. Similarly, rilpivirine AUC, Cmax and Ctrough increased by 6%, 10% and 21%, respectively, in the presence of dolutegravir. Dolutegravir and rilpivirine can be coadministered without dosage adjustment for either agent.

Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Ford SL, Gould E, Chen S, et al. Antimicrob Agents Chemother, 2013, 57(11):5472-7.

View all available interactions with Rilpivirine (RPV) by clicking here.